dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Morote Robles, Joan |
dc.contributor.author | Celma Domènech, Ana |
dc.contributor.author | Regis Plácido, Lucas |
dc.contributor.author | Mast, Richard |
dc.contributor.author | Torres Ramirez, Inés de |
dc.contributor.author | Santamaria Margalef, Anna |
dc.contributor.author | Planas Morin, Jacques |
dc.contributor.author | Trilla Herrera, Enric |
dc.contributor.author | Triquell Llauradó, Marina |
dc.contributor.author | Borque Fernando, Ángel |
dc.contributor.author | Semidey Raven, Maria Eugenia |
dc.date.accessioned | 2022-09-07T12:33:14Z |
dc.date.available | 2022-09-07T12:33:14Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Mast R, et al. Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. Cancers. 2022 May;14(10):2374. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/8063 |
dc.description | Clinically significant prostate cancer; Predictive model; Prostate-specific antigen |
dc.description.abstract | This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;14(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Imatgeria per ressonància magnètica |
dc.subject | Pròstata - Biòpsia |
dc.subject.mesh | Magnetic Resonance Imaging |
dc.subject.mesh | Biopsy |
dc.subject.mesh | Prostatic Neoplasms |
dc.subject.mesh | /diagnostic imaging |
dc.title | Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers14102374 |
dc.subject.decs | imagen por resonancia magnética |
dc.subject.decs | biopsia |
dc.subject.decs | neoplasias de la próstata |
dc.subject.decs | /diagnóstico por imagen |
dc.relation.publishversion | https://doi.org/10.3390/cancers14102374 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Morote J, Trilla E] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Borque-Fernando A] Department of Urology, Hospital Miguel Servet, IIS-Aragon, 50009 Zaragoza, Spain. [Triquell M, Celma A, Regis L, Planas J] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mast R] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [de Torres IM, Semidey ME] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Santamaría A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 35625978 |
dc.identifier.wos | 000801886000001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |